|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:1212-1214
© 2004 The American Association for Thoracic Surgery
Brief communication |
a Thoracic Surger and the Multidisciplinary Pulmonary Program, Policlinico University Tor Vergata, Rome, Italy
Received for publication August 1, 2003; revisions received October 2, 2003; revisions received November 3, 2003; accepted for publication December 3, 2003.
* Address for reprints: Tommaso C. Mineo, MD, Cattedra di Chirurgia Toracica, Università Tor Vergata, Policlinico Tor Vergata, V.le Oxford 81 00133 Rome, Italy
mineo{at}med.uniroma2.it
|
Bilateral lung volume reduction (LVR) can significantly improve the functional capacity of selected patients with severe emphysema and an upper-lobe predominance of disease.1,2 However, because of its palliative nature, postoperative improvements usually peak within the first 6 months and slowly decline subsequently, eventually returning back to the baseline status in most patients. Little is known, however, as to whether redo LVR3 can be reasonably proposed in selected patients after bilateral LVR.
Herein we describe 4 patients with upper-lobe prevailing emphysema who underwent completion lobectomy (CL) as a redo LVR after a previous bilateral operation. The patients, all men, were operated on between September 2001 and October 2002. All patients gave their written, informed consent. The mean interval between bilateral LVR and CL was 59 months. After the bilateral operation, marked improvements occurred in pulmonary function measures: +360 mL in forced expiratory volume in 1 second (FEV1), 1170 mL in residual volume, +125 m in the 6-minute walking test, and +5.25 mm Hg in arterial oxygen tension. Afterward, the FEV1 annual decline averaged 0.23 ± 0.09 L at 24 months and ±0.08 L at 36 months.
CL was performed when FEV1 returned to baseline values and high-resolution computed tomography showed severe emphysematous lung destruction that was prevailing in 1 upper lobe (Figure 1, 1 and 2). Before CL, all patients were receiving maximized medical therapy and underwent a 4-week respiratory rehabilitation program.
|
|
|
This is the first report dealing with redo LVR in patients with cigarette smokingrelated severe emphysema and upper lobe predominance. Stammberger and coworkers3 have already reported on a patient with
1-antytripsin deficiency emphysema, who also benefited from redo LVR.
CL resulted in meaningful functional improvements in 3 of 4 patients, and in no instance did pulmonary hypertension, which can occur after bilateral LVR,4 develop. Nonetheless, 1 patient died of respiratory failure after surgery. We believe that he probably had too-advanced disease in the remaining lung tissue, with a scarcely heterogeneous pattern of emphysema.
Anatomic resection is considered contraindicated in patients with emphysema because of the risk of removal of functioning lung tissue. However, lobectomy has been recently reported5 as a successful LVR procedure in patients with severely emphysematous lung lobes. Despite the very limited cohort, our results suggest that in stringently selected patients with a completely destroyed and functionally useless residual upper lobe, CL can be followed by meaningful improvements in respiratory function measures and exercise capacity.
We advise that CL be strictly performed in patients who have already benefited meaningfully from the first reduction, because it is highly unlikely that a patient who did not benefit from LVR initially will improve after CL. We believe that one reliable way of monitoring the patient's condition is observing the FEV1 decay. In fact, FEV1 is a reliable measure of the severity of chronic obstructive pulmonary disease and is correlated with the clinical benefit of LVR. Our data suggest that FEV1 decay is maximal between 12 and 24 months and becomes less steep subsequently. However, the unavoidable and sometimes accelerated functional decline observed after LVR emphasizes that more efforts must be devoted to improve the current surgical techniques.
We conclude that in carefully selected patients, CL can prolong the benefits of LVR, a surgical option that continues to stimulate active investigation and to raise concerns and skepticism but that can undoubtedly offer some hope to properly selected patients with severe emphysema.
Acknowledgments
This study was performed within the Research Fellowship Program Tecnologie e Terapie Avanzate in Chirurgia awarded by the Tor Vergata University.
Footnotes
This research was supported by Ministero dellUniversità e della Ricerca Scientificá e Tecnologica (MURST) Cofinanziamento (COFIN) grants 9906274194-06 and 2001061191-001, Consiglio Nazionale della Ricerca (CNR) CU0100935 2002, and Centro di Eccellenza 2001.
References
1-antitrypsin deficiency. Ann Thorac Surg. 2000;69:632633This article has been cited by other articles:
![]() |
F. Tacconi, E. Pompeo, D. Forcella, M. Marino, D. Varvaras, and T. C. Mineo Lung Volume Reduction Reoperations Ann. Thorac. Surg., April 1, 2008; 85(4): 1171 - 1177. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |